Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Roche Fails Phase 3 Trial in Non-Hodgkin’s Lymphoma

By Stephanie Guzowski | July 18, 2016

Swiss drugmaker Roche’s blood cancer drug Gazyva (obinutuzumab) failed to show significant improvements against its older, best-seller MabThera/Rituxan (rituximab) in a late-stage study, the company announced Monday.

Gazyva’s trial missed its primary endpoint in improving progression-free survival in patients with previously untreated diffuse large B-cell lymphoma. The trial, called GOYA, involved nearly 1,500 patients.

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma (NHL), accounting for up to 30 percent of newly diagnosed cases in the U.S. DLBCL is an aggressive lymphoma, which can arise in lymph nodes or outside the lymphatic system, in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain.

The failed trial is considered a setback for Roche, who is counting on new cancer treatments to help offset competition from biosimilars. Interestingly, two previous studies showed that Gazyva performed better than MabThera/Rituxan, when combined with chemotherapy, in patients with previously untreated follicular lymphoma or chronic lymphocytic leukemia. “We were hopeful we could show a similar result for people with DLBCL and once again improve on the standard of care,” said Roche’s chief medical officer Sandra Horning.

Similar to MabThera/Rituxan, Gazyva, a monoclonal antibody, targets CD20, a protein expressed on certain B cells, in treating blood cancers.

Another approach to immunotherapy in treating blood cancers is CAR-T therapy: These therapies involve extracting a patient’s T cells, genetically modifying the T cells to express CARs that target the antigen CD19 — a protein expressed on the cell surface of B-cell lymphomas and leukemias — and then reinfusing the engineered cells into the patient. CAR-T therapy has shown successful results in treating leukemia and lymphoma, yet the experimental treatment’s side effects are being considered.

Data from Gazyva’a trial will be presented at an upcoming medical meeting, Roche announced. “We will continue to analyze the GOYA data to better understand the results, and to study other investigational treatments in this disease with the goal of further helping these patients,” said Horning.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE